Valeo Financial Advisors LLC Buys Shares of 101,576 Roivant Sciences Ltd. $ROIV

Key Points

• Valeo Financial Advisors LLC purchased 101,576 shares of Roivant Sciences Ltd. for approximately $1,145,000 during the second quarter.
• Several other institutional investors have increased their holdings in Roivant Sciences, with hedge funds owning 64.76% of the company's stock.
• Roivant Sciences has seen analysts' price targets increase, with ratings ranging from Strong Buy to Sell, and a consensus price target of $19.94.

Valeo Financial Advisors LLC acquired a new position in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 101,576 shares of the company's stock, valued at approximately $1,145,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Parallel Advisors LLC grew its holdings in Roivant Sciences by 80.5% in the first quarter. Parallel Advisors LLC now owns 2,485 shares of the company's stock worth $25,000 after purchasing an additional 1,108 shares during the last quarter. UMB Bank n.a. grew its stake in Roivant Sciences by 112.7% during the 1st quarter. UMB Bank n.a. now owns 4,143 shares of the company's stock worth $42,000 after buying an additional 2,195 shares during the last quarter. Russell Investments Group Ltd. grew its stake in Roivant Sciences by 94.8% during the 1st quarter. Russell Investments Group Ltd. now owns 4,588 shares of the company's stock worth $46,000 after buying an additional 2,233 shares during the last quarter. Fifth Third Bancorp grew its stake in shares of Roivant Sciences by 59.3% during the first quarter. Fifth Third Bancorp now owns 5,118 shares of the company's stock worth $52,000 after acquiring an additional 1,905 shares during the last quarter. Finally, GAMMA Investing LLC grew its position in Roivant Sciences by 83.0% during the 1st quarter. GAMMA Investing LLC now owns 6,493 shares of the company's stock worth $66,000 after purchasing an additional 2,945 shares during the last quarter. Hedge funds and other institutional investors own 64.76% of the company's stock.

Roivant Sciences Stock Performance

Shares of NASDAQ ROIV opened at $16.12 on Wednesday. The company's fifty day moving average price is $13.16 and its 200 day moving average price is $11.68. Roivant Sciences Ltd. has a 1 year low of $8.73 and a 1 year high of $16.79. The company has a market capitalization of $11.01 billion, a PE ratio of -23.03 and a beta of 1.20.

Analyst Ratings Changes

ROIV has been the topic of several research analyst reports. Weiss Ratings reiterated a "sell (d+)" rating on shares of Roivant Sciences in a research note on Saturday, September 27th. JPMorgan Chase & Co. boosted their price target on Roivant Sciences from $16.00 to $20.00 and gave the company an "overweight" rating in a research note on Thursday, September 18th. Leerink Partners upped their target price on Roivant Sciences from $18.00 to $22.00 and gave the company an "outperform" rating in a research report on Thursday, September 18th. HC Wainwright upped their target price on Roivant Sciences from $18.00 to $20.00 and gave the company a "buy" rating in a research report on Thursday, September 18th. Finally, The Goldman Sachs Group upped their price objective on shares of Roivant Sciences from $20.00 to $24.00 and gave the company a "buy" rating in a report on Thursday, September 18th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $19.94.

Insiders Place Their Bets

In other news, CEO Eric Venker sold 683,818 shares of the stock in a transaction that occurred on Friday, September 19th. The stock was sold at an average price of $14.95, for a total transaction of $10,223,079.10. Following the transaction, the chief executive officer owned 1,969,767 shares in the company, valued at $29,448,016.65. This trade represents a 25.77% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Matthew Gline bought 3,315 shares of the firm's stock in a transaction dated Thursday, September 18th. The shares were acquired at an average price of $15.07 per share, for a total transaction of $49,957.05. Following the transaction, the chief executive officer directly owned 17,287,081 shares in the company, valued at approximately $260,516,310.67. This represents a 0.02% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders have sold 3,686,749 shares of company stock worth $50,302,987. 10.80% of the stock is owned by corporate insiders.

Roivant Sciences Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.

Want to see what other hedge funds are holding ROIV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.